What is the 13F Pro Quality Score for EVMN?

13F Pro ranks Evommune, Inc. (EVMN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View EVMN's current score at https://13fpro.ai/research/EVMN (free sign-up required for the full ranking).

Where does 13F Pro source EVMN data?

All Evommune, Inc. fundamentals and ownership data come directly from SEC EDGAR. Evommune, Inc. files with the SEC under CIK 2044725. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is EVMN in?

Evommune, Inc. (EVMN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is EVMN research updated on 13F Pro?

EVMN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Evommune, Inc.(EVMN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 2044725 EVMN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $13.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

EVMN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Evommune, Inc. (EVMN), a Healthcare sector company. EVMN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $13.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Evommune, Inc. reports net income of $-21.7M, free cash flow of $-27.6M. Top institutional holders of EVMN by reported 13-F value include EQT Fund Management S.a r.l., RA CAPITAL MANAGEMENT, L.P., Pivotal bioVenture Partners Investment Advisor, based on the most recent SEC filings. EVMN trades on the NYSE exchange and files with the SEC under CIK 2044725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EVMN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Evommune, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-21.7M

Free Cash Flow

Q1 2026

$-27.6M

ROIC

Q1 2026

-7.9%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+85.7% YoY

$13.0MFY 2025

FY24 $7.0MFY25 $13.0M

Net Income

-3.1% YoY

$-68.9MFY 2025

FY24 $-66.8MFY25 $-68.9M

Operating Income

-15.8% YoY

$-81.1MFY 2025

FY24 $-70.0MFY25 $-81.1M

EPS (Diluted)

+75.2% YoY

$-11.22FY 2025

FY24 $-45.29FY25 $-11.22

Total Assets

+195.8% YoY

$224.9MFY 2025

FY24 $76.1MFY25 $224.9M

Op. Cash Flow

-31.4% YoY

$-76.4MFY 2025

FY24 $-58.2MFY25 $-76.4M

Metric	FY 2025	FY 2024
Revenue	$13.0M +85.7%	$7.0M
Net Income	$-68.9M -3.1%	$-66.8M
Operating Income	$-81.1M -15.8%	$-70.0M
EPS (Diluted)	$-11.22 +75.2%	$-45.29
Total Assets	$224.9M +195.8%	$76.1M
Operating Cash Flow	$-76.4M -31.4%	$-58.2M

AI Insight: EVMN Financial Trends

Evommune remains pre-revenue with mounting operating losses, though a sharp equity swing from -$183M to $305M signals significant new capital raised.

• Revenue is $0M in both Q4 2025 and Q1 2026 — company is fully pre-commercial with no product sales.

• Equity surged from -$183M in Q3 2025 to $305M in Q1 2026, implying substantial capital raises over two quarters.

• Operating cash outflow widened from -$17M in Q4 2025 to -$28M in Q1 2026, accelerating cash burn.

⚠ Operating losses of -$30M in Q4 2025 and -$24M in Q1 2026 show persistent burn; runway depends entirely on future capital raises.

⚠ No debt reported across all periods — clean balance sheet liability-side, but equity financing dilution risk remains.

AI Insight: EVMN Ratio Trends

Evommune shows very limited financial data, but ROE and ROIC losses narrowed sharply from Q4 2025 to Q1 2026.

• ROE improved from -55.0% in Q4 2025 to -28.5% in Q1 2026, a 26.5pp reduction in annualized losses.

• ROIC narrowed from -57.8% in Q4 2025 to -31.5% in Q1 2026, suggesting lower capital consumption quarter-over-quarter.

• ROA improved from -50.3% in Q4 2025 to -26.9% in Q1 2026, indicating better asset utilization efficiency.

⚠ All available return metrics remain deeply negative; the company is still burning capital at a significant rate.

⚠ OpMargin, NPM, and D/E are entirely absent across all three quarters, leaving leverage and profitability structure opaque.

Get alerted when EVMN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Evommune, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of EVMN

EQT Fund Management S.a r.l.
$113.3M4,929,633 sh
RA CAPITAL MANAGEMENT, L.P.
$80.3M3,494,638 sh
Pivotal bioVenture Partners Investment Advisor LLC
$44.3M1,926,943 sh
Andera Partners
$43.6M1,897,362 sh
RTW INVESTMENTS, LP
$34.5M1,502,235 sh
MPM BioImpact LLC
$33.5M1,455,863 sh
Nan Fung Group Holdings Ltd
$33.1M1,441,032 sh
SymBiosis Capital Partners, LLC
$29.4M1,280,778 sh
EVENTIDE ASSET MANAGEMENT, LLC
$27.8M1,209,129 sh
JANUS HENDERSON GROUP PLC
$20.6M896,700 sh

Fund	Value	Shares
EQT Fund Management S.a r.l.	$113.3M	4,929,633
RA CAPITAL MANAGEMENT, L.P.	$80.3M	3,494,638
Pivotal bioVenture Partners Investment Advisor LLC	$44.3M	1,926,943
Andera Partners	$43.6M	1,897,362
RTW INVESTMENTS, LP	$34.5M	1,502,235
MPM BioImpact LLC	$33.5M	1,455,863
Nan Fung Group Holdings Ltd	$33.1M	1,441,032
SymBiosis Capital Partners, LLC	$29.4M	1,280,778
EVENTIDE ASSET MANAGEMENT, LLC	$27.8M	1,209,129
JANUS HENDERSON GROUP PLC	$20.6M	896,700

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put EVMN on your watchlist

Track score changes the day Evommune, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is EVMN a good stock to buy?

13F Pro's AI-powered analysis of Evommune, Inc. (EVMN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EVMN are available on the EVMN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own EVMN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EVMN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Evommune, Inc.'s investment landscape.